uniQure Faces Class Action Lawsuit Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Notice: Kahn Swick & Foti LLC reminds investors who purchased uniQure shares between September 24 and October 31, 2025, to file lead plaintiff applications by April 13, 2026, to participate in the ongoing class action lawsuit against the company.
- Lawsuit Background: uniQure and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the anticipated accelerated approval of its drug candidate AMT-130, leading to significant investor losses.
- Stock Price Plunge: Following the November 3, 2025 announcement that the FDA no longer deemed the data for AMT-130 adequate for BLA submission, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29, severely impacting investor confidence.
- Legal Consultation Opportunity: Investors seeking to understand their legal rights and the potential impact of this case on their economic losses can contact KSF law firm for free, highlighting the case's implications and investors' rights to recovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 16.890
Low
33.00
Averages
49.88
High
70.00
Current: 16.890
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: On March 5 and 6, 2026, FDA officials publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly harm the company's reputation and stock price.
- Securities Class Action: Hagens Berman is investigating uniQure for failing to disclose interactions with the FDA during the class period from September 24 to October 31, 2025, potentially leading to investor losses and having profound implications for the company's legal and financial standing.
- Critical Deadline: Investors must apply to be Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in the loss of their claims, directly impacting their rights and protections as shareholders.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to assist in the investigation and influencing uniQure's future trajectory.
See More
Reminder for uniQure Shareholders on Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval for its pivotal study on Huntington's disease treatment, resulting in investor losses when the true information was revealed, highlighting significant transparency issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise, urging investors to select qualified legal counsel wisely.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support and potential compensation in the class action.
See More
uniQure Faces Class Action Lawsuit; Investors Encouraged to Claim
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks for the company.
- Allegation Details: The complaint alleges that uniQure made materially false and misleading statements during the class period, failing to disclose that the design of its Pivotal Study was not fully FDA approved, which could delay its BLA submission and impact the company's prospects.
- Investor Rights: Investors must apply by April 13, 2026, to be appointed as lead plaintiff, highlighting the potential impact of these legal challenges on the company's stock price and investor confidence.
- Legal Consultation Available: Bragar Eagel & Squire offers free consultations, allowing investors to contact attorneys via phone or email to understand their legal rights and potential claims.
See More
uniQure Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that the deadline to file lead plaintiff applications in the uniQure N.V. securities class action lawsuit is April 13, 2026, for those who purchased shares between September 24 and October 31, 2025, risking loss of claims if not filed on time.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of accelerated FDA approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 announcement that the FDA no longer deemed the data sufficient for a Biologics License Application, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, resulting in significant financial losses for investors.
- Legal Consultation Services: ClaimsFiler offers free legal consultation services, allowing investors to access information and connect with Kahn Swick & Foti, LLC lawyers to understand their legal options and protect their rights in the securities class action lawsuit.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants failed to adequately disclose that the design of uniQure's pivotal study for its leading drug candidate in Huntington's Disease was not fully approved by the FDA, resulting in investor losses when the true information was revealed, highlighting a lack of operational transparency.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel, avoiding firms that lack experience and resources, to ensure effective legal representation and support in the class action process.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly undermine investor confidence.
- Securities Lawsuit Update: Hagens Berman is updating its investigation into uniQure, urging investors who purchased shares between September 24 and October 31, 2025, to submit Lead Plaintiff applications by the April 13, 2026 deadline, highlighting the urgency of the situation.
- False Statement Allegations: The securities class action alleges that uniQure failed to disclose critical interactions with the FDA and utilized a pivotal study design that was not approved, potentially leading to significant investor losses and legal repercussions.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about uniQure to assist in the investigation, as the SEC's Whistleblower program offers rewards of up to 30% of any successful recovery, providing an additional layer of protection and incentive for investors.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: On March 5 and 6, 2026, FDA officials publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly harm the company's reputation and stock price.
- Securities Class Action: Hagens Berman is investigating uniQure for failing to disclose interactions with the FDA during the class period from September 24 to October 31, 2025, potentially leading to investor losses and having profound implications for the company's legal and financial standing.
- Critical Deadline: Investors must apply to be Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in the loss of their claims, directly impacting their rights and protections as shareholders.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to assist in the investigation and influencing uniQure's future trajectory.
See More
Reminder for uniQure Shareholders on Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval for its pivotal study on Huntington's disease treatment, resulting in investor losses when the true information was revealed, highlighting significant transparency issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise, urging investors to select qualified legal counsel wisely.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support and potential compensation in the class action.
See More
uniQure Faces Class Action Lawsuit; Investors Encouraged to Claim
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks for the company.
- Allegation Details: The complaint alleges that uniQure made materially false and misleading statements during the class period, failing to disclose that the design of its Pivotal Study was not fully FDA approved, which could delay its BLA submission and impact the company's prospects.
- Investor Rights: Investors must apply by April 13, 2026, to be appointed as lead plaintiff, highlighting the potential impact of these legal challenges on the company's stock price and investor confidence.
- Legal Consultation Available: Bragar Eagel & Squire offers free consultations, allowing investors to contact attorneys via phone or email to understand their legal rights and potential claims.
See More
uniQure Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that the deadline to file lead plaintiff applications in the uniQure N.V. securities class action lawsuit is April 13, 2026, for those who purchased shares between September 24 and October 31, 2025, risking loss of claims if not filed on time.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of accelerated FDA approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 announcement that the FDA no longer deemed the data sufficient for a Biologics License Application, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, resulting in significant financial losses for investors.
- Legal Consultation Services: ClaimsFiler offers free legal consultation services, allowing investors to access information and connect with Kahn Swick & Foti, LLC lawyers to understand their legal options and protect their rights in the securities class action lawsuit.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants failed to adequately disclose that the design of uniQure's pivotal study for its leading drug candidate in Huntington's Disease was not fully approved by the FDA, resulting in investor losses when the true information was revealed, highlighting a lack of operational transparency.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel, avoiding firms that lack experience and resources, to ensure effective legal representation and support in the class action process.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly undermine investor confidence.
- Securities Lawsuit Update: Hagens Berman is updating its investigation into uniQure, urging investors who purchased shares between September 24 and October 31, 2025, to submit Lead Plaintiff applications by the April 13, 2026 deadline, highlighting the urgency of the situation.
- False Statement Allegations: The securities class action alleges that uniQure failed to disclose critical interactions with the FDA and utilized a pivotal study design that was not approved, potentially leading to significant investor losses and legal repercussions.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about uniQure to assist in the investigation, as the SEC's Whistleblower program offers rewards of up to 30% of any successful recovery, providing an additional layer of protection and incentive for investors.
See More
